Arrowhead Pharmaceuticals Inc. (ARWR)
$73.91
$-0.50
(-0.67%)
As on 12-Jun-2026 13:36EDT
Market cap
$10,295 Mln
Revenue (TTM)
$622 Mln
P/E Ratio
--
P/B Ratio
16.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
27.9
-
Debt to Equity
1.4
-
Book Value
$--
-
EPS
$-2.1
-
Face value
--
-
Shares outstanding
140,857,021
10 Years Aggregate
CFO
$-277.87 Mln
EBITDA
$-815.57 Mln
Net Profit
$-860.32 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arrowhead Pharmaceuticals (ARWR)
| 11.3 | -4.9 | 27.2 | 341.5 | 27.9 | -3.6 | 28.9 |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Arrowhead Pharmaceuticals (ARWR)
| 253.1 | -38.3 | -24.6 | -38.8 | -13.6 | 21.0 | 410.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arrowhead Pharmaceuticals (ARWR)
|
73.9 | 10,295.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 16.8 |
| 283.0 | 40,461.0 | 4,286.9 | 577.2 | 9.8 | 88.2 | 76.3 | 37.6 | |
| 221.7 | 13,001.6 | 867.5 | 506.6 | -2.8 | -- | 23.9 | 23.8 | |
| 53.1 | 13,246.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 17.5 | 6.8 | |
| 131.2 | 16,655.9 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 179.4 | 30,617.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.8 | 5.0 | |
| 468.8 | 12,973.2 | 2,678.3 | 460.4 | 21.1 | 103.2 | 28.6 | 21.9 | |
| 614.6 | 66,620.0 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15.5 | 2.1 | |
| 540.6 | 23,340.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.3 | 4.0 | |
| 444.1 | 113,407.9 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
Shareholding Pattern
View DetailsAbout Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of... angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California. Read more
-
CEO, President & Director
Dr. Christopher R. Anzalone Ph.D.
-
CEO, President & Director
Dr. Christopher R. Anzalone Ph.D.
-
Headquarters
Pasadena, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Arrowhead Pharmaceuticals (ARWR)
What is the current share price of Arrowhead Pharmaceuticals Inc (ARWR) Today?
The share price of Arrowhead Pharmaceuticals Inc (ARWR) is $73.91 (NASDAQ) as of 12-Jun-2026 13:36 EDT. Arrowhead Pharmaceuticals Inc (ARWR) has given a return of 27.91% in the last 3 years.
What is the current PB & PE ratio of Arrowhead Pharmaceuticals Inc (ARWR)?
Since, TTM earnings of Arrowhead Pharmaceuticals Inc (ARWR) is negative, P/E ratio is not available.
The P/B ratio of Arrowhead Pharmaceuticals Inc (ARWR) is 16.77 times as on 05-Jun-2026, a 312 premium to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2,869.63
|
10.04
|
|
2024
|
-3.94
|
12.74
|
|
2023
|
-14.05
|
10.63
|
|
2022
|
-19.80
|
8.77
|
|
2021
|
-46.33
|
15.96
|
What is the 52 Week High and Low of Arrowhead Pharmaceuticals Inc (ARWR)?
The 52-week high and low of Arrowhead Pharmaceuticals Inc (ARWR) are Rs 82.00 and Rs 14.30 as of 13-Jun-2026.
What is the market cap of Arrowhead Pharmaceuticals Inc (ARWR)?
Arrowhead Pharmaceuticals Inc (ARWR) has a market capitalisation of $ 10,295 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Arrowhead Pharmaceuticals Inc (ARWR)?
Before investing in Arrowhead Pharmaceuticals Inc (ARWR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.